Literature DB >> 11166786

Neurogenic bladder in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine.

K Satoh1, M Motomura, H Suzu, Y Nakao, T Fujimoto, T Fukuda, S Nakane, T Nakamura, K Eguchi.   

Abstract

Autonomic dysfunction, as well as neuromuscular involvement, is a common manifestation of Lambert-Eaton myasthenic syndrome (LEMS). Dry mouth and impotence have been described as typical features of autonomic dysfunction, but neurogenic bladder is infrequent or subclinical in LEMS. We report a patient with neurogenic bladder secondary to LEMS whose condition responded to 3,4-diaminopyridine (3,4-DAP). In this patient's serum, results of repeated measurement with P/Q-type VGCC antibodies proved positive, but not with N-type VGCC and synaptotagmin antibodies. A review of the literature turned up a few patients with voiding dysfunction related to LEMS, but no urodynamic studies were done on these patients. Ours is the first case in which 3,4-DAP was efficacious in treating LEMS and neurogenic bladder. Responses of 3,4-DAP in urodynamic studies suggest that in this LEMS patient neurogenic bladder was caused by defective neurotransmission both in the autonomic detrusor and skeletal abdominal muscles.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166786     DOI: 10.1016/s0022-510x(00)00460-3

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  3 in total

1.  4-aminopyridine improves lower urinary tract symptoms in a patient with benign prostatic hyperplasia and downbeat nystagmus syndrome.

Authors:  Michael Strupp; Katharina Feil; Stanislavs Bardins; Raphaela Waidelich
Journal:  Int Neurourol J       Date:  2014-12-29       Impact factor: 2.835

2.  Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine.

Authors:  Sabine Lindquist; Martin Stangel
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-30       Impact factor: 2.570

3.  Urinary incontinence as a possible signal of neuromuscular toxicity during immune checkpoint inhibitor treatment: Case report and retrospective pharmacovigilance study.

Authors:  Yizhang Hu; Wenchao Lu; Borui Tang; Zhixia Zhao; Zhuoling An
Journal:  Front Oncol       Date:  2022-09-12       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.